Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494905 | 0.86 | MAPK10 (0.40) | SLC6A4SLC6A2SLC6A3KDM1A | |
| SCHEMBL4497491 | 0.86 | AKR1C3 (0.38) | SLC6A4MEN1MAPTKMT2ATDP1 | |
| SCHEMBL4507517 | 0.84 | ADRB2 (0.34) | SLC6A4SLC6A2SLC6A3TDP1CHEK1 | |
| SCHEMBL4509585 | 0.84 | SMN1; SMN2 (0.37) | PIK3CBMEN1MAPTKMT2ATDP1 | |
| SCHEMBL4505054 | 0.84 | SMYD3 (0.37) | SLC6A4MEN1MAPTKMT2ATDP1 | |
| SCHEMBL4493813 | 0.74 | ALDH1A1 (0.37) | SLC6A4SLC6A2MEN1MAPTKMT2A | |
| SCHEMBL4491405 | 0.71 | KCNN1 (0.41) | MEN1KMT2A | |
| SCHEMBL4496674 | 0.71 | ACHE (0.43) | SLC6A4SLC6A3PIK3CBMEN1MAPT | |
| SCHEMBL4496490 | 0.65 | HDAC6 (0.41) | MEN1MAPTKMT2A | |
| SCHEMBL4514352 | 0.65 | GAA (0.45) | MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | SLC6A4 3690/4885SLC6A2 4703/4885SLC6A3 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.